241 related articles for article (PubMed ID: 21954337)
1. Low expression of TBX4 predicts poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Zong M; Meng M; Li L
Int J Mol Sci; 2011; 12(8):4953-63. PubMed ID: 21954337
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
[TBL] [Abstract][Full Text] [Related]
3. Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.
Qi T; Han J; Cui Y; Zong M; Liu X; Zhu B
J Clin Pathol; 2008 Jan; 61(1):49-58. PubMed ID: 17412869
[TBL] [Abstract][Full Text] [Related]
4. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
[TBL] [Abstract][Full Text] [Related]
5. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
6. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models.
Shinkai K; Nakano K; Cui L; Mizuuchi Y; Onishi H; Oda Y; Obika S; Tanaka M; Katano M
Int J Cancer; 2016 Jul; 139(2):433-45. PubMed ID: 26939718
[TBL] [Abstract][Full Text] [Related]
7. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Koga A; Sato N; Kohi S; Yabuki K; Cheng XB; Hisaoka M; Hirata K
Pancreatology; 2017; 17(1):115-122. PubMed ID: 28012880
[TBL] [Abstract][Full Text] [Related]
8. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
9. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
11. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.
Xue YZ; Wu TL; Wu YM; Sheng YY; Wei ZQ; Lu YF; Yu LH; Li JP; Li ZS
Tumour Biol; 2013 Oct; 34(5):2857-61. PubMed ID: 23681804
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC).
Sun Y; Cao S; Li Z; Liu X; Xu J; Tian Y; Shen S; Zhou Y
Int J Med Sci; 2021; 18(9):2051-2062. PubMed ID: 33850476
[No Abstract] [Full Text] [Related]
13. Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.
Sakugawa C; Haruyama Y; Tanaka H; Fukushima T; Kawaguchi M; Kataoka H
BMC Res Notes; 2017 Dec; 10(1):674. PubMed ID: 29202869
[TBL] [Abstract][Full Text] [Related]
14. [Expression of B cell transposition gene 3 in pancreatic ductal adenocarcinoma and its prognostic value].
Chen J; Zhou ZC; Liu WB; Wang J; Chen XJ; Shen YY; Zhong ZX
Zhonghua Wai Ke Za Zhi; 2017 Nov; 55(11):863-867. PubMed ID: 29136736
[No Abstract] [Full Text] [Related]
15. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features.
Zhao L; Cui Q; Lu Z; Chen J
Pancreas; 2012 Mar; 41(2):206-11. PubMed ID: 21792082
[TBL] [Abstract][Full Text] [Related]
17. AHNAK2 is a potential prognostic biomarker in patients with PDAC.
Lu D; Wang J; Shi X; Yue B; Hao J
Oncotarget; 2017 May; 8(19):31775-31784. PubMed ID: 28423668
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients with pancreatic ductal adenocarcinoma.
Jiang B; Zhou L; Lu J; Wang Y; Liu C; Liang Z; Zhou W; You L; Guo J
J Gastroenterol Hepatol; 2021 Feb; 36(2):507-515. PubMed ID: 32875609
[TBL] [Abstract][Full Text] [Related]
19. A novel methylation signature predicts inferior outcome of patients with PDAC.
Gu M; Sun J; Zhang S; Chen J; Wang G; Ju S; Wang X
Aging (Albany NY); 2021 Jan; 13(2):2851-2863. PubMed ID: 33550277
[TBL] [Abstract][Full Text] [Related]
20. Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma.
Ding YC; Yu W; Ma C; Wang Q; Huang CS; Huang T
Int J Clin Exp Pathol; 2014; 7(11):8065-70. PubMed ID: 25550852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
